Journal
SCIENTIFIC REPORTS
Volume 11, Issue 1, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41598-021-86017-4
Keywords
-
Categories
Funding
- Lupus Research Institute
- National Psoriasis Foundation
- BD Biosciences Research Grant
- University of Florida
- American Association Immunologists
- Novel Grant from the Alliance for Lupus Research
- McKnight pre-doctoral fellowships
Ask authors/readers for more resources
Autoimmune diseases are largely caused by activated lymphocytes producing a pathogenic cytokine environment. One approach to treating autoimmune diseases involves targeting the SOCS1 pathway with a peptide mimic of the SOCS1 kinase inhibitory region (SOCS1-KIR). This treatment has shown promise in reducing auto-reactive lymphocyte effector functions and mitigating autoimmune pathologies.
Autoimmune diseases are driven largely by a pathogenic cytokine milieu produced by aberrantly activated lymphocytes. Many cytokines, including interferon gamma (IFN-gamma), utilize the JAK/STAT pathway for signal propagation. Suppressor of Cytokine Signaling-1 (SOCS1) is an inducible, intracellular protein that regulates IFN-gamma signaling by dampening JAK/STAT signaling. Using Fas deficient, MRL/MpJ-Fas(lpr)/J (MRL/lpr) mice, which develop lupus-like disease spontaneously, we tested the hypothesis that a peptide mimic of the SOCS1 kinase inhibitory region (SOCS1-KIR) would inhibit lymphocyte activation and modulate lupus-associated pathologies. Consistent with in vitro studies, SOCS1-KIR intraperitoneal administration reduced the frequency, activation, and cytokine production of memory CD8(+) and CD4(+) T lymphocytes within the peripheral blood, spleen, and lymph nodes. In addition, SOCS1-KIR administration reduced lymphadenopathy, severity of skin lesions, autoantibody production, and modestly reduced kidney pathology. On a cellular level, peritoneal SOCS1-KIR administration enhanced Foxp3 expression in total splenic and follicular regulatory T cells, reduced the effector memory/naive T lymphocyte ratio for both CD4(+) and CD8(+) cells, and reduced the frequency of GL7(+) germinal center enriched B cells. Together, these data show that SOCS1-KIR treatment reduced auto-reactive lymphocyte effector functions and suggest that therapeutic targeting of the SOCS1 pathway through peptide administration may have efficacy in mitigating autoimmune pathologies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available